GRACEcast Lung Cancer Audio
136 episodes - English - Latest episode: over 10 years ago - ★★★★★ - 1 ratingOncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Squamous Lung Cancer Part 5, Q and A Session (audio)
December 20, 2013 08:34 - 13 minutes - 12.9 MBDr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.
Squamous Lung Cancer, Part 4: Immunotherapy (audio)
December 10, 2013 23:43 - 7 minutes - 6.64 MBDr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.
Squamous Lung Cancer, Part 3: Treatment (audio)
December 08, 2013 23:07 - 12 minutes - 12 MBDr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.
Squamous Lung Cancer, Part 2: Genomic Testing (audio)
December 06, 2013 18:02 - 11 minutes - 10.7 MBDr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.
Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (audio)
December 02, 2013 23:40 - 15 minutes - 14 MBDr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)
September 04, 2013 19:32 - 5 minutes - 5.05 MBDr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)
August 31, 2013 01:56 - 5 minutes - 5.25 MBDr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.
ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio)
August 26, 2013 23:56 - 5 minutes - 4.96 MBDr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)
August 26, 2013 23:54 - 5 minutes - 5.32 MBDr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)
August 23, 2013 18:48 - 9 minutes - 9.04 MBDr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.
ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio)
August 23, 2013 18:46 - 7 minutes - 6.72 MBDr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.
ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (audio)
August 16, 2013 21:19 - 4 minutes - 3.84 MBDr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.
ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)
August 16, 2013 21:18 - 6 minutes - 6.13 MBDr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (audio)
August 15, 2013 23:43 - 12 minutes - 11.9 MBDr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.
ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (audio)
August 14, 2013 00:03 - 6 minutes - 5.85 MBDr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)
August 13, 2013 01:43 - 8 minutes - 7.99 MBDr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
ASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (audio)
August 11, 2013 02:15 - 8 minutes - 8.07 MBDr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (audio)
August 07, 2013 05:08 - 7 minutes - 7.14 MBDr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (audio)
June 09, 2013 07:38 - 21 minutes - 19.8 MBDr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
Dr. Antoinette Wozniak on Small Cell Lung Cancer: Introduction, Diagnosis, and Staging (audio)
May 30, 2013 07:11 - 16 minutes - 15.3 MBDr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (audio)
May 20, 2013 22:50 - 19 minutes - 17.9 MBDr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)
May 17, 2013 01:17 - 11 minutes - 10.7 MBDr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (audio)
May 13, 2013 19:58 - 12 minutes - 11.6 MBDr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)
April 07, 2013 00:14 - 3 minutes - 3.45 MBDr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (audio)
March 30, 2013 01:31 - 8 minutes - 7.47 MBDr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.
Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)
March 29, 2013 23:46 - 5 minutes - 5.04 MBDr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)
March 23, 2013 03:04 - 10 minutes - 9.78 MBDr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (audio)
March 18, 2013 23:58 - 18 minutes - 17.3 MBDr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (audio)
March 12, 2013 22:29 - 10 minutes - 9.56 MBDr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.
Dr. Harpole on Lung Surgery: Advances in Lung Cancer Staging (audio)
February 11, 2013 22:51 - 11 minutes - 10.3 MBDr. David Harpole of Duke University reviews advances in lung cancer surgery, focusing in this first part on the evolution of techniques to improve staging of lung cancer.
Managing Pulmonary Complications of Lung Cancer Treatment: Targeted Therapy and Radiation-Induced Lung Damage (audio)
October 25, 2012 02:15 - 14 minutes - 13.2 MBDr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by EGFR inhibitors or chest radiation.
Managing Pulmonary Complications of Lung Cancer Treatment: Chemo-Induced Lung Damage (Audio)
October 15, 2012 02:33 - 17 minutes - 16 MBDr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by chemotherapy commonly used for treating lung cancer.
ASCO 2012 Lung Cancer Highlights: Question and Answer Session (audio)
September 29, 2012 19:30 - 20 minutes - 18.9 MBDrs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.
ASCO 2012 LC Highlights: Dr. Joel Neal on Molecular Targets in Squamous NSCLC (audio)
September 21, 2012 15:00 - 4 minutes - 4.17 MBDr. Joel Neal presents interesting early data demonstrating that squamous NSCLC often features identifiable molecular markers that can potentially be targeted by novel therapies.
ASCO 2012 LC Highlights: Dr. Joel Neal on the SELECT Trial of Tarceva (Erlotinib) As Adjuvant Therapy for EGFR Mutation-Positive Advanced NSCLC (audio)
September 16, 2012 23:11 - 4 minutes - 4.5 MBDr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer.
ASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (audio)
September 12, 2012 07:29 - 5 minutes - 4.84 MBDr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.
ASCO 2012 LC Highlights: Dr. Joel Neal on the MEK Inhibitor Selumetinib in KRAS Mutation-Positive NSCLC (audio)
September 11, 2012 03:56 - 5 minutes - 4.79 MBDr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).
ASCO 2012 LC Highlights: Dr. Joel Neal on Anti-PD-1 Immunotherapy for Advanced NSCLC (audio)
September 05, 2012 00:01 - 7 minutes - 7.08 MBDr. Joel Neal describes the very encouraging data on anti-PD-1 immunotherapy with BMS-936558/MDX-1106 in patients with advanced non-small cell lung cancer (NSCLC).
ASCO 2012 LC Highlights: Dr. Mark Socinski on Key Trials in Small Cell Lung Cancer (audio)
August 30, 2012 01:00 - 8 minutes - 7.47 MBDr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.
ASCO 2012 LC Highlights: Dr. Mark Socinski on TAILOR Trial in EGFR wild type Advanced NSCLC (audio)
August 27, 2012 03:45 - 7 minutes - 6.58 MBDr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.
ASCO 2012 LC Highlights: Dr. Mark Socinski on Single Agent vs Doublet Chemo for PS2 (audio)
August 19, 2012 07:43 - 6 minutes - 6.31 MBDr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.
ASCO 2012 Lung Cancer Highlights: Dr. Mark Socinski on PARAMOUNT Continuation Maintenance Therapy Trial (audio)
August 16, 2012 22:13 - 8 minutes - 7.94 MBDr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.
Immunotherapy for Lung Cancer: Q and A Session (audio)
July 16, 2012 20:35 - 13 minutes - 12.5 MBDrs. Ramaswamy Govindan from Washington University and Julie Brahmer from Johns Hopkins University answer questions about the current evidence and emerging research on immune-based treatments for lung cancer.
Immunotherapy for Lung Cancer: Yervoy, anti-PD-1, Reolysin, & Talactoferrin by Dr. J. Brahmer (audio)
June 14, 2012 17:36 - 23 minutes - 21.7 MBDr. Julie Brahmer reviews science and early trial results for immunotherapies for lung cancer ranging from cancer vaccines to anti-cancer viruses.
Immunotherapies for Lung Cancer: MAGE-A3, Stimuvax, and Lucanix, by Dr. R. Govindan (audio)
June 07, 2012 06:58 - 21 minutes - 19.9 MBDr. Ramaswamy Govindan provides a summary of the science behind several promising immunotherapies for lung cancer and the clinical trials that could lead to them being integrated into our treatment plans.
Molecular Markers in Lung Cancer Pt 6: Dr. Glen Goss on Incorporating Markers Across a Health Care System (audio)
May 23, 2012 06:00 - 25 minutes - 23 MBDr. Glen Goss, University of Ottawa and NCI-Canada Lung Cancer Committee chair, discusses the potential and limitations of integrating molecular marker studies in advanced non-small cell lung cancer patients across a health care system.
Molecular Markers in Lung Cancer Pt 5: Dr. David Spigel on Incorporating Targets into Clinical Trials (audio)
May 10, 2012 22:22 - 24 minutes - 22.5 MBDr. David Spigel, Sarah Cannon Cancer Center, discusses the benefits and challenges of conducting trials that include patient subgroups based on molecular markers.
Molecular Markers in Lung Cancer Pt 4: Broadening Use of Markers in Practice -- Panel Discussion (audio)
April 28, 2012 23:52 - 16 minutes - 15.6 MBPanel discussion with 4 expert thought leaders in lung cancer about how we might best approach testing clinically relevant molecular targets in lung cancer patients.
Molecular Markers in Lung Cancer Pt 3: Who to Test and What to Test For -- Panel Discussion (audio)
April 23, 2012 02:05 - 17 minutes - 16 MBPanel discussion with 4 expert thought leaders in lung cancer about the prevalence of critical molecular markers in different clinical and histologic groups of lung cancer patients.
Molecular Markers in Lung Cancer Pt 2: Dr. Alice Shaw on Mutation Patterns by Patient Features (audio)
April 14, 2012 23:04 - 10 minutes - 9.93 MBDr. Alice Shaw from Massachusetts General Hospital reviews the frequency of molecular markers in lung cancer by patient sex, smoking status, race, and histology.